Regeneron Pharmaceuticals on Tuesday announced that a phase 3 trial still in progress of an antibody cocktail has shown a 100 percent prevention of symptomatic COVID-19 infections. Interim results also show approximately 50 percent lower overall rates of infection across all patients. For infections that did take place, peak virus levels were decreased and they…